| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:30 - 08:40 | Opening Ceremony | ||||||
| 08:40 - 09:00 | [Keynote Speech] Right Choice Beyond Survival: How Taiwan is Pioneering Quality and Equity in Breast Cancer Care Through Value-Based Reform |
Chung-Liang Shih
|
|||||
| 09:00 - 09:30 | Session(1) Early Onset Breast Cancer: Current Knowledge and Gaps |
Kyong Hwa Park
|
|||||
| 09:30 - 10:00 | Session (1) Role of Platinum in Adjuvant/Neoadjuvant Treatment in TNBC | ||||||
| 10:00 - 10:40 | Session (1) Redefining the Role of TKIs in HER2-Positive mBC: From Systemic Control to CNS Penetration |
Nancy Lin
|
|||||
| 10:40 - 11:00 | Coffee Break | ||||||
| 11:00 - 11:40 | Session (2) Navigating the Complexities of Treatment in HR+ HER2- Metastatic Breast Cancer: Tailoring CDK4/6 Inhibitors to Meet Individual Patient Needs | ||||||
| 11:40 - 12:20 | Session (2) The Practice of Treating HR+/HER2- Early Breast Cancer is Evolving: Broading the Impact of CDK4/6 Inhibitors |
Peter Fasching
|
|||||
| 12:20 - 13:05 | Luncheon Symposium (1) Maximizing Treatment Benefit and Overall Survival in HER2- Negative MBC | ||||||
| 13:05 - 13:20 | Coffee Break | ||||||
| 13:20 - 14:00 | Session (2) The Sustainable Efficacy of CDK4/6 Inhibitor in HR+/Her2- Node+ High Risk Early Breast Cancer |
Michael Gnant
|
|||||
| 14:00 - 14:30 | Session (2) Personalized Neo-Adjuvant Strategies for Hormone Receptor-Positive Early Breast Cancer |
Marc Thill
|
|||||
| 14:30 - 15:10 | Session (2) Choosing Wisely:TS-1 for HR+ EBC | ||||||
| 15:10 - 15:30 | Coffee Break | ||||||
| 15:30 - 16:10 | Session (2) Transforming Treatment Landscape of HR+ mBC: Integrating Genomic Biomarkers to Drive Precision Medicine |
Naoto T. Ueno
|
|||||
| 16:10 - 16:50 | Session (2) The Next Wave of Endocrine and Target Therapy for HR+/HER2- Metastatic Breast Cancer |
Peter Schmid
|
|||||
| 16:50 - 17:30 | Session (3) Unlocking the Potential of ADC: Transforming Breast Cancer Outcomes Across HER2 Expression Spectrum (MBC) |
Naoto T. Ueno
|
|||||
| 17:30 - 18:00 | Session (3) Current Status and Emerging Approaches in HER2+ Metastatic Breast Cancer |
Giampaolo Bianchini
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 10:10 - 10:30 | [TBCS-GBCC Joint Session] Axillary management following NAC: Surgical Oncologists’ point of views | ||||||
| 10:30 - 10:50 | [TBCS-GBCC Joint Session] Axillary management following NAC: Medical Oncologists’ point of views | ||||||
| 10:50 - 11:10 | [TBCS-GBCC Joint Session] Axillary management following NAC: Radiation Oncologists’ point of views | ||||||
| 11:10 - 11:30 | [TBCS-GBCC Joint Session] Wrap up: Current guidelines of Axillary management following NAC | ||||||
| 11:30 - 12:00 | [TBCS-GBCC Joint Session] Panel Discussion | ||||||
| 14:05 - 14:30 | [Young Doctors Forum] Beyond the White Coat: Challenges Facing Young Female Breast Oncologists and How to Address Them |
Kelly Hunt
|
|||||
| 14:30 - 14:55 | [Young Doctors Forum] Global Perspectives: Navigating Career Pathways in Breast Cancer Treatment for Young Doctors |
Tristen Park
|
|||||
| 14:55 - 15:00 | [Young Doctors Forum] Q&A | ||||||
| 15:00 - 15:05 | Coffee Break | ||||||
| 15:05 - 16:30 | Young Doctors Debate |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:10 - 08:50 | Breakfast Symposium: Beyond Cancer-Related Fatigue: Exploring Immunomodulatory Strategies to Reshape Breast Cancer Care | ||||||
| 08:50 - 09:20 | Session (4) The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer |
Mehra Golshan
|
|||||
| 09:20 - 09:50 | Session (4) Omission of Radiation Therapy Post Breast Conserving Surgery |
Boon Chua
|
|||||
| 09:50 - 10:05 | Coffee Break | ||||||
| 10:05 - 10:35 | Session (4) Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy |
Judy C. Boughey
|
|||||
| 10:35 - 11:05 | Session (4) Setting the Standard for the Future of Cancer Surgery |
Kelly Hunt
|
|||||
| 11:05 - 11:45 | Session (5) Shifting Paradigms in mTNBC - Advancing Sacituzumab Towards the Frontline |
Sherene Loi
|
|||||
| 11:45 - 12:25 | Session (5) A New Era in the Treatment of Metastatic Triple-Negative Breast Cancer: Who, When, and Why to Use Immunotherapy and Antibody-Drug Conjugates | ||||||
| 12:25 - 13:10 | Luncheon Symposium (2) Advances in Dual HER2 Inhibition: Shaping the Future of HER2-Positive Breast Cancer Care |